Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.
Novo Nordisk and Eli Lilly's dominance over the budding weight loss drug market could eventually face threats from formidable rivals.
"There are a number of others trying to break into both small and large, but when I step back, I do think that Amgen has a real shot at being disruptive and challenging Eli Lilly and Novo," William Blair & Company analyst Matt Phipps told CNBC.12% since CEO Bob Bradley on Thursday said he was"very encouraged" by an ongoing mid-stage study on MariTide. But it isn't the only company that has a chance to upend the market.
Less frequent doses of MariTide may also cause fewer side effects than other weight loss treatments, Phipps noted. Many patients stop taking existing drugs due to nausea and vomiting. But while Zepbound activates a second hormone receptor called GIP, Amgen's drug blocks it. Wegovy does not target GIP, which suppresses appetite like GLP-1 but may also improve how the body breaks down sugar and fat.
Eli Lilly is also developing an oral drug called orforglipron, which targets GLP-1. The company is slated to release late-stage trial data on the pill and retatrutide in 2025.In February, the companies also posted positive mid-stage trial data on survodutide in patients with a severe form of liver disease.as a treatment for obesity or liver disease in 2027 or 2028, as long as trial data is favorable, according to a Reuters interview.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo Nordisk, Eli Lilly drop on Amgen competition concernsNovo Nordisk, Eli Lilly drop on Amgen competition concerns
Read more »
Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slideAmgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.
Read more »
Amgen scraps experimental weight loss pill, moves forward with injectionAmgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Read more »
Amgen scraps experimental weight loss pill, moves forward with injectionAmgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli Lilly.
Read more »
European markets higher; French banks gain on profit beats as Novo Nordisk slidesEuropean stock markets traded in the green on Friday, rounding off a broadly negative week dominated by corporate earnings.
Read more »
Wegovy maker Novo Nordisk down 4%, heads for worst day since OctoberAnalysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.
Read more »